Titan Pharmaceuticals and Molteni receive European regulatory approval for Probuphine
Titan Pharma announced the EC has approved Sixmo®-buprenorphine, the brand name for Probuphine® (buprenorphine) implant in the EU. The EC's decision applies to all 28 EU member states, where Sixmo is now approved for substitution treatment for opioid dependence in clinically stable adult patients. June 26, 2019